Rossari Biotech Limited (ROSSARI.BO)
INR 804.75
(-0.97%)
INR 804.75
(-0.97%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 432.55 Million | 1.52 Billion | 293.58 Million | 477.67 Million | 568.29 Million | 711.77 Million |
| Net Income | 1.77 Billion | 1.44 Billion | 1.36 Billion | 1.06 Billion | 880.59 Million | 633.92 Million |
| Depreciation & Amortization | 603.9 Million | 629.31 Million | 480.55 Million | 228.29 Million | 168.52 Million | 122.64 Million |
| Deferred income taxes | - | -482.95 Million | -533.45 Million | -339.49 Million | -194.9 Million | - |
| Stock-based compensation | 9.17 Million | 9.43 Million | 18.31 Million | 16.27 Million | 4.63 Million | - |
| Change in working capital | -1.56 Billion | -271.97 Million | -1.12 Billion | -483.05 Million | -310.68 Million | 113.91 Million |
| Other non-cash items | 171.33 Million | 197.93 Million | 85.89 Million | -12.73 Million | 20.13 Million | -158.7 Million |
| Investing Cash Flow | -1.03 Billion | -1.8 Billion | -2.98 Billion | -371.79 Million | -1.9 Billion | -364.22 Million |
| Investments in PPE | -1.31 Billion | -328.76 Million | -382.25 Million | -580.84 Million | -759.71 Million | -439.91 Million |
| Acquisitions | -177.33 Million | -985.31 Million | -3.55 Billion | -43.39 Million | -43.93 Million | 10 Thousand |
| Investment purchases | -90.23 Million | -534.37 Million | -75.1 Million | 57.13 Million | -181.31 Million | 5.8 Million |
| Sales/Maturities of investments | 466.27 Million | - | 15.54 Million | 137.22 Million | 59.73 Million | 69.39 Million |
| Other Investing Activities | 458.02 Million | 39.5 Million | 1 Billion | 58.09 Million | -977.79 Million | 490 Thousand |
| Financing Cash Flow | 161.85 Million | 608.55 Million | 2.91 Billion | -245.92 Million | 1.56 Billion | -291.5 Million |
| Debt repayment | -318.99 Million | -655.01 Million | -48.12 Million | -610.12 Million | -24.16 Million | -521.54 Million |
| Dividends payments | -27.58 Million | -27.53 Million | -27.53 Million | -25.38 Million | -26.48 Million | -105.92 Million |
| Common Stock Repurchased | - | 1.31 Billion | - | -38.95 Million | 631.65 Million | - |
| Common Stock Issuance | 38.45 Million | 42.12 Million | 3.01 Billion | 426.53 Million | 1 Billion | - |
| Other Financing Activities | 313.36 Million | -61.05 Million | -21.5 Million | 2 Million | -11.58 Million | 335.96 Million |
| Accounts receivables | -1.12 Billion | -279.69 Million | -425.28 Million | -404.5 Million | -204.06 Million | -344.23 Million |
| Accounts payables | 496.34 Million | 400 Thousand | -222.78 Million | 241.7 Million | -68.97 Million | 672.19 Million |
| Inventory | -938.48 Million | 7.32 Million | -481.85 Million | -320.25 Million | -37.65 Million | -214.02 Million |
| Other working capital | 496.34 Million | - | 9.44 Million | - | - | -30 Thousand |
| Cash at beginning of period | 691.98 Million | 374.77 Million | 152.08 Million | 292.11 Million | 57.42 Million | 6.25 Million |
| Cash at end of period | 251.7 Million | 698.32 Million | 374.77 Million | 152.08 Million | 292.11 Million | 57.42 Million |
| Capital Expenditure | -1.31 Billion | -328.76 Million | -382.25 Million | -580.84 Million | -759.71 Million | -439.91 Million |
| Effect of forex changes on cash | -2.54 Million | 2.02 Million | - | 10 Thousand | -20 Thousand | -4.88 Million |
| Net cash flow / Change in cash | -440.28 Million | 323.55 Million | 222.69 Million | -140.03 Million | 234.69 Million | 51.17 Million |
| Free Cash Flow | -880.28 Million | 1.19 Billion | -88.67 Million | -103.17 Million | -191.42 Million | 271.86 Million |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 348.99 Million | 341.32 Million | 1.77 Billion | 343.9 Million | 329.48 Million | 292.19 Million |
| Depreciation & Amortization | - | - | 603.9 Million | 150.88 Million | 151.14 Million | 141.14 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | 9.17 Million | 9.17 Million | - | - | - |
| Change in working capital | - | - | -1.56 Billion | - | - | - |
| Other non-cash items | -348.99 Million | -350.49 Million | 171.33 Million | -343.9 Million | -329.48 Million | -292.19 Million |
| Investing Cash Flow | - | - | -1.03 Billion | - | - | - |
| Investments in PPE | - | - | -1.31 Billion | - | - | - |
| Acquisitions | - | - | -177.33 Million | - | - | - |
| Investment purchases | - | - | -90.23 Million | - | - | - |
| Sales/Maturities of investments | - | - | 466.27 Million | - | - | - |
| Other Investing Activities | - | - | 458.02 Million | - | - | - |
| Financing Cash Flow | - | - | 161.85 Million | - | - | - |
| Debt repayment | - | - | -318.99 Million | - | - | - |
| Dividends payments | - | - | -27.58 Million | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 38.45 Million | - | - | - |
| Other Financing Activities | - | - | 313.36 Million | - | - | - |
| Accounts receivables | - | - | -1.12 Billion | - | - | - |
| Accounts payables | - | - | 496.34 Million | - | - | - |
| Inventory | - | - | -938.48 Million | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | - | - | 691.98 Million | 506.18 Million | 176.7 Million | 698.32 Million |
| Cash at end of period | - | - | 251.7 Million | 343.9 Million | 506.18 Million | 292.19 Million |
| Capital Expenditure | - | - | -1.31 Billion | - | - | - |
| Effect of forex changes on cash | - | - | -2.54 Million | - | - | - |
| Net cash flow / Change in cash | - | - | -440.28 Million | -162.28 Million | 329.48 Million | -406.13 Million |
| Free Cash Flow | - | - | -880.28 Million | 343.9 Million | 329.48 Million | 292.19 Million |
HINDMILL
SUNPHARMA
AMNPLST
BVRDF
ALORD
SWSDF